Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 6/20 | 0.35 |
| ▸ | MMP3 | P08254 | 4/20 | 0.35 |
| ▸ | MMP12 | P39900 | 2/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP7 | P09237 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15689707 | 0.95 | KDM4E (0.38) | KDM4EPOLBALDH1A1TDP1L3MBTL1 | |
| SCHEMBL41818 | 0.74 | KDM4E (0.42) | KDM4EPOLBALDH1A1TDP1L3MBTL1 | |
| Acetic Acid SCHEMBL14990893 | 0.72 | KDM4E (0.39) | KDM4EPOLBALDH1A1TDP1L3MBTL1 | |
| SCHEMBL16921604 | 0.71 | KDM4E (0.59) | KDM4EPOLBALDH1A1TDP1L3MBTL1 | |
| SCHEMBL13395919 | 0.66 | KDM4E (0.46) | KDM4EPOLBALDH1A1TDP1L3MBTL1 | |
| SCHEMBL8663329 | 0.64 | KDM4E (0.69) | KDM4EPOLBALDH1A1TDP1L3MBTL1 | |
| SCHEMBL16901820 | 0.63 | ELANE (0.49) | POLBALDH1A1TDP1L3MBTL1SLC22A12 | |
| SCHEMBL356631 | 0.63 | KDM4E (0.48) | KDM4EMMP3MMP12MMP1MMP7 | |
| SCHEMBL806247 | 0.62 | ELANE (0.55) | ALDH1A1TDP1L3MBTL1SLC22A12GAA | |
| SCHEMBL6912133 | 0.62 | CYP3A4 (0.54) | KDM4EPOLBALDH1A1TDP1SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9616133-B2 | Orally administrable gallium compositions and methods of use | BERNSTEIN LAWRENCE R (US) | 2017-04-11 | — | — | US | claimed |
| US-20160317669-A1 | ORALLY ADMINISTRABLE GALLIUM COMPOSITIONS AND METHODS OF USE | BERNSTEIN LAWRENCE R (US) | 2016-11-03 | — | — | US | claimed |
| US-9040063-B2 | Orally administrable gallium compositions and methods of use | BERNSTEIN LAWRENCE RICHARD (US) | 2015-05-26 | — | — | US | claimed |
| US-20140024633-A1 | Orally administrable gallium compositions and methods of use | BERNSTEIN LAWRENCE RICHARD (US) | 2014-01-23 | — | — | US | claimed |
| EP-1993567-A2 | ORALLY ADMINISTRABLE GALLIUM COMPOSITIONS AND METHOD OF USE | BERNSTEIN, Lawrence Richard (US) | 2008-11-26 | — | — | EP | claimed |
| WO-2007100382-A2 | ORALLY ADMINISTRABLE GALLIUM COMPOSITIONS AND METHOD OF USE | BERNSTEIN LAWRENCE R (US) | 2007-09-07 | — | — | WO | claimed |
| US-20070098815-A1 | Orally Administrable Gallium Compositions and Methods of Use | BERNSTEIN LAWRENCE R | 2007-05-03 | — | — | US | claimed |
| US-9616133-B2 | Orally administrable gallium compositions and methods of use | BERNSTEIN LAWRENCE R (US) | 2017-04-11 | — | — | US | disclosed |
| US-9492551-B2 | Orally administrable gallium compositions and methods of use | BERNSTEIN LAWRENCE R (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160317669-A1 | ORALLY ADMINISTRABLE GALLIUM COMPOSITIONS AND METHODS OF USE | BERNSTEIN LAWRENCE R (US) | 2016-11-03 | — | — | US | disclosed |
| US-9040063-B2 | Orally administrable gallium compositions and methods of use | BERNSTEIN LAWRENCE RICHARD (US) | 2015-05-26 | — | — | US | disclosed |
| US-20150038477-A1 | ORALLY ADMINISTRABLE GALLIUM COMPOSITIONS AND METHODS OF USE | BERNSTEIN LAWRENCE R (US) | 2015-02-05 | — | — | US | disclosed |
| US-20140024633-A1 | Orally administrable gallium compositions and methods of use | BERNSTEIN LAWRENCE RICHARD (US) | 2014-01-23 | — | — | US | disclosed |
| WO-2005058331-A1 | USE OF GALLIUM TO TREAT INFLAMMATORY ARTHRITIS | TITAN PHARMACEUTICALS, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| EP-1218011-A4 | GALLIUM COMPLEXES OF 3-HYDROXY-4-PYRONES TO TREAT INFECTION BY INTRACELLULAR PROKARYOTES, DNA VIRUSES AND RETROVIRUSES | BERNSTEIN LAWRENCE R (US) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003053347-A2 | GALLIUMCOMPLEXES OF 3-HYDROXY-4-PYRONES TO TREAT MYCOBACTERIAL INFECTIONS | BERNSTEIN LAWRENCE R (US) | 2003-07-03 | — | — | WO | disclosed |
| US-20030083308-A1 | Gallium complexes of 3-hydroxy-4-pyrones to treat infection by intracellular prokaryotes and DNA viruses | BERNSTEIN LAWRENCE R (US) | 2003-05-01 | — | — | US | disclosed |
| EP-1218011-A1 | GALLIUM COMPLEXES OF 3-HYDROXY-4-PYRONES TO TREAT INFECTION BY INTRACELLULAR PROKARYOTES, DNA VIRUSES AND RETROVIRUSES | Bernstein, Lawrence R. (US) | 2002-07-03 | — | — | EP | disclosed |
| US-20020068761-A1 | Gallium complexes of 3-hydroxy-4-pyrones to treat mycobacterial infections | BERNSTEIN LAWRENCE R (US) | 2002-06-06 | — | — | US | disclosed |
| WO-2001024799-A1 | GALLIUM COMPLEXES OF 3-HYDROXY-4-PYRONES TO TREAT INFECTION BY INTRACELLULAR PROKARYOTES, DNA VIRUSES AND RETROVIRUSES | BERNSTEIN LAWRENCE R (US) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083308-A1 | Gallium complexes of 3-hydroxy-4-pyrones to treat infection by intracellular prokaryotes and DNA viruses | MALT1, HMGB3, HMGB2 | KDM4E 866/4885POLB 374/4885ALDH1A1 2337/4885 |
| US-20020068761-A1 | Gallium complexes of 3-hydroxy-4-pyrones to treat mycobacterial infections | PGLS, MDH1, GCDH | KDM4E 757/4885POLB 1306/4885ALDH1A1 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.